GET DAILY SIGNALSBioVie Inc. (BIVI) Faces a Steep Climb Toward the $5.25 Analyst Target
Key Takeaways
- The $5.25 central target is the arithmetic mean of two verified analyst price targets, $5.00 and $5.51, both carrying a "Strong Buy" rating.
- With shares of BioVie Inc. (BIVI) recently trading near $1.37, reaching $5.25 would require roughly a +283% gain, a very large move for any security.
- The two targets form a narrow range of $5.00 to $5.51, but only two analysts cover the company, so the sample is thin and should be read with caution.
- The bull case rests on late-stage clinical candidates, including bezisterim (NE3107) in Phase 3 for Alzheimer's disease and BIV201 in Phase 3 for ascites tied to liver cirrhosis.
- The biggest risks are that BioVie is a clinical-stage company with no product revenue, recurring operating losses, and a micro-cap valuation of roughly $12 million, leaving it exposed to dilution and binary trial outcomes.
- You can track BioVie's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for deeper context.
- For automated insights across the broader market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
BioVie remains thinly covered by Wall Street. Two analysts currently publish price targets for the stock, according to data aggregated from S&P Global and other providers: a low of $5.00 and a high of $5.51. The arithmetic mean of those two figures is about $5.26, which rounds to the $5.25 central target used here. Both analysts rate the stock "Strong Buy," reflecting a generally optimistic but very small consensus.
Firms that have published ratings on BioVie Inc. (BIVI) in the past include Cantor Fitzgerald (Overweight), Oppenheimer (Outperform), ThinkEquity (Buy), and EF Hutton (Buy), though these historical ratings do not necessarily correspond to the two current targets and should not be treated as a live consensus. With only two data points and a clinical-stage business model, the average is best understood as a broad directional view rather than a precise forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. A target this far above the current price signals that covering analysts expect substantial value to be created only if pivotal trial data succeed and the company secures a path toward commercialization.
Current Market Position and Path Toward the Target
BioVie Inc. (BIVI) shares recently closed near $1.37, within a 52-week range of $0.82 to $3.79. At that level, the stock would need to climb roughly +283% to reach the $5.25 central target, a move that qualifies as very large and well beyond ordinary market appreciation for a single 12-month period. A rally of that magnitude would almost certainly require a definitive, positive clinical or regulatory catalyst rather than gradual multiple expansion.
The path would likely run through clinical milestones: positive results for bezisterim in Alzheimer's or Parkinson's disease, or progress on BIV201, which holds FDA Fast Track and Orphan Drug designations for ascites. Because the company generates no product revenue, reported EPS is deeply negative, and valuation is driven by the risk-adjusted value of its pipeline rather than earnings or sales.
What Could Support a Move Toward the Target
The central argument for higher prices is the pipeline. Bezisterim (NE3107) is an orally administered, anti-inflammatory small molecule in Phase 3 development for mild-to-moderate Alzheimer's disease and in Phase 2b for Parkinson's disease, with additional work in long COVID. BIV201, a continuous-infusion formulation of terlipressin, is in Phase 3 for ascites caused by liver cirrhosis and benefits from Fast Track and Orphan Drug designations. Any statistically significant, clinically meaningful readout could dramatically re-rate a company valued at only about $12 million, since biotech valuations are highly sensitive to binary data events. A thin float and small share count can also amplify upside when positive news lands.
What Could Prevent the Target From Being Reached
The risks are equally substantial. BioVie has no approved products or recurring revenue, reported a trailing net loss of roughly $22 million, and holds only about $9 million in cash as of its most recent quarter, meaning additional capital raises and shareholder dilution are likely. Phase 3 trials frequently fail, and even promising mid-stage data does not guarantee success in larger, placebo-controlled studies. The stock has already fallen sharply from its 52-week high of $3.79, reflecting investor caution around execution and financing. A negative readout, a financing at unfavorable terms, or a reverse stock split to maintain Nasdaq listing compliance would all pressure shares and make the $5.25 target far less attainable.
Technical Levels and Market Structure
BIVI trades below both its 50-day and 200-day moving averages, near $1.64 and $1.52 respectively, indicating weak near-term trend structure. The 52-week low of $0.82 is the most relevant long-term support, while the stock's decline from a September peak above $2.30 leaves resistance overhead in the $1.60-to-$1.80 and $2.00-to-$2.30 zones. The $5.00-to-$5.51 analyst range itself sits well above the entire 52-week trading history, underscoring that reaching it would require a fundamental, catalyst-driven repricing rather than a technical breakout.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the specific horizon for each of the two BioVie targets is not disclosed. Investors should watch the company's next earnings report, estimated for early November, for cash position, burn rate, and financing updates. The most consequential catalysts are clinical: topline data and regulatory updates on bezisterim and BIV201, along with any new funding announcements, analyst initiations or target revisions, and Nasdaq listing compliance developments. Given the concentration of the thesis in two late-stage assets, trial data will matter far more than quarterly financials.
Using AI Tools for Ongoing Monitoring
In my view, systematic signals can help investors stay on top of momentum shifts without constant manual review. I have found Tickeron’s AI-driven tools useful for scanning broader market conditions alongside individual names like BIVI.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BIVI in +9.77% Uptrend, advancing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIVI advanced for three days, in 194 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIVI's RSI Indicator exited the oversold zone, 25 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on BIVI as a result. In 71 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for BIVI just turned positive on October 21, 2026. Looking at past instances where BIVI's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
BIVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for BIVI crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BIVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.437) is normal, around the industry mean (3.104). P/E Ratio (-0.567) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. BIVI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement